Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
← catalyst calendarSponsored by Sana Biotechnology (industry) · SANA — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
16actual
Sites
10
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-02 | actual | When the study began enrolling |
| Primary completion | 2025-11-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2038-11-04 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
Intervention
- Drug: SC291 — also filed as Cyclophosphamide, Fludarabine
Primary outcome
what the primary-completion date above is the date OFEvaluate safety and tolerability of SC291
measured 24 months
Permalink · SANA's whole pipeline · Catalyst calendar · Every registered study · What changed